摘要
目的探讨术中黏膜下注射吡柔比星（THP）及术后膀胱灌注预防膀胱癌术后复发的疗效。方法45例膀胱尿路上皮癌患者均行经尿道膀胱肿瘤电切术（TURBT），术中黏膜下注射吡柔比星及术后膀胱灌注1年。结果45例获得随访，随访时间36～60个月，中位时间为45个月。患者1、2、3年复发率为8．8％（4／45）、14．1％（7／45）、17．8％（8／45）；复发患者肿瘤分级和分期进展率为12．5％。88．9％膀胱癌患者无明显不良反应或轻度膀胱局部症状。全身不良反应率为2．2％。结论术中黏膜下注射吡柔比星及术后膀胱灌注是一种安全、有效的方法，可有效降低膀胱癌术后复发率。
Objective To evaluate the effect of submucosal injection and intravesical instillation of pirarubicin（THP） for prevention of postoperative recurrence of bladder cancer. Methods Forty -five cases of bladder cancer were treated with transurethral resection of bladder tumor（TURBT） plus submucosal injection and intravesical instillation of pirarubicin. Results Forty - five patients were followed up for 36 - 60 months. The recurrence rates in 1st, 2nd and 3rd year after surgery were 8.8% （4/45） ,14. 1% （7/45） and 17. 8% （8/45）. Among the patient with recurrence, 12.5% had high tumor grade. 88.9% of the patients had no overt side effects or only mild irritating symtom. 2.2% of the patients had systemic side effect. Conclu- sions Submucosal injection and intravesical instillation of pirarubicin （THP） for prevention of postoperative recurrence is a safe and effect therapy for bladder cancer.
出处
《中国实用医刊》
2011年第13期30-31,共2页
Chinese Journal of Practical Medicine
关键词
膀胱癌
黏膜下注射
膀胱灌注
吡柔比星
Bladder cancer
Submucosal injection
Intravesical instillation
Pirarubicin
